The planned campus at the New Albany International Business Park will use a flexible, modular design combining drug substance and drug product manufacturing with digital and automation technologies.
The agreement gives Apollo-managed funds and affiliates a non-controlling interest in a newly created entity that will hold Bayer’s LARC portfolio.
The acquisition comes as Bayer seeks to reinforce its position in ophthalmology amid growing biosimilar competition facing Eylea, which it co-developed with Regeneron.